PEGBIO CO-B (02565) rose more than 6%, reaching 5.94% at the time of writing, with its stock price at HK$65.95 and a trading volume of HK$5.08 million.

The company announced that the original lock-up period, which had been extended once before, was set to expire on December 31, 2025. As of the announcement date, cornerstone investors collectively held 9.58 million H-shares, representing approximately 3.43% of the company's total issued H-shares.

Recently, the company received a notice from cornerstone investors stating their agreement not to sell any related H-shares in any manner from the original lock-up expiration date (previously extended) until April 30, 2026.

PEGBIO CO-B views this second lock-up extension as a sign of confidence from cornerstone investors in the company's future prospects, driven by its progress in R&D capabilities and significant clinical milestones. The cornerstone investors will continue to review the company's performance and may consider further extending the lock-up period based on real-time developments and achieved milestones.